Cocrystal Pharma Inc (COCP) Stock Price, Quote & News

Latest News on COCP

Mar 31, 2025, 8:00 AM EDT - 2 days ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 6, 2025, 8:00 AM EST - 27 days ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Dec 31, 2024, 2:21 PM EST - 3 months ago

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Dec 31, 2024, 8:00 AM EST - 3 months ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Aug 19, 2024, 4:05 PM EDT - 8 months ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 15, 2024, 3:00 PM EDT - 8 months ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

May 13, 2024, 8:00 AM EDT - 11 months ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 1, 2024, 8:00 AM EDT - 1 year ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 5, 2024, 8:30 AM EST - 1 year ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Dec 6, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Nov 29, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 27, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 9, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Apr 10, 2023, 8:30 AM EDT - 2 years ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Jan 26, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 23, 2023, 9:00 AM EST - 2 years ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Dec 1, 2022, 4:05 PM EST - 2 years ago

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Nov 17, 2022, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Nov 1, 2022, 4:05 PM EDT - 2 years ago

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Oct 26, 2022, 8:00 AM EDT - 2 years ago

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

Oct 5, 2022, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Oct 3, 2022, 4:05 PM EDT - 2 years ago

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Aug 8, 2022, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Aug 3, 2022, 9:00 AM EDT - 2 years ago

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

May 18, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

May 11, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

Apr 19, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference

Apr 12, 2022, 11:08 AM EDT - 3 years ago

Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

Apr 12, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

Mar 23, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

Mar 22, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

Mar 10, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

Jan 27, 2022, 12:22 PM EST - 3 years ago

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

Jan 27, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Jan 6, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Dec 22, 2021, 11:43 AM EST - 3 years ago

Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant

Dec 22, 2021, 8:00 AM EST - 3 years ago

Cocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

Dec 2, 2021, 8:00 AM EST - 3 years ago

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets' Channelchek Virtual Roadshow

Dec 1, 2021, 4:05 PM EST - 3 years ago

Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021

Nov 8, 2021, 8:00 AM EST - 3 years ago

Cocrystal Pharma's SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

Nov 1, 2021, 7:24 PM EDT - 3 years ago

Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19

Nov 1, 2021, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment

Oct 14, 2021, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

Oct 6, 2021, 8:49 AM EDT - 3 years ago

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

Jul 29, 2021, 10:10 AM EDT - 3 years ago

Market Cap	14.45M
Revenue (ttm)	0.00
Net Income (ttm)	-17.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,100
Avg Vol	22,784
Day's Range	N/A - N/A
Shares Out	10.17M
Stochastic %K	20%
Beta	2.21
Analysts	Strong Sell
Price Target	$8.33